IPIRA Startups

IPIRA Startups

Clarity Movement Co.

Brief Description

Clarity Movement Co. is a team of passionate engineers and scientists focused on making a positive impact in the world by tackling the global air pollution crisis. We leverage our expertise in air sensing technology, IoT devices, and data analytics to create solutions that empower communities to make more informed decisions and improve quality of life. Having already developed the world’s most accurate low-cost particulate matter sensor, Clarity is now deploying the next generation of dense air quality monitoring networks around the world to build smarter cities through...

Chiron Corporation

Brief Description

Chiron Corporation was an American biotechnology company engaged in biopharmaceuticals, vaccines and blood testing.

Timeline 1981. Company founded 1990. Company Initial Public Offering on NASDAQ under the ticker symbol of CHIR. 2006. Acquired by Novartis Inventors

Henry Chang, Felix Karim, Gerald Rubin, Marc Therrien, David Wassarman

Tsingpo Tech, LLC

Brief Description

Tsingpo Tech is developing a technology invented at UC Berkeley for 3-dimensional chemical sensing on 2-dimensional surfaces.

Timeline 2018. Company founded Inventors

Takeshi Hayasaka, Liwei Lin, YuMeng (Simon) Liu

Cell-X

Brief Description

Editing T-cells with nanopore-electroporation to improve CRISPR-Cas9 editing capabilities.

Timeline 2021. Company founded Inventors

YuHong Cao, Jennifer Doudna, Enbo Ma, Peidong Yang

4D Molecular Therapeutics LLC

Brief Description 4D Molecular Therapeutics is a global leader in gene therapy product research & development using scientific innovation to unlock the full potential of gene therapy for patients with genetic diseases. Their robust discovery platform, termed Directed Vector Evolution, empowers us to create customized gene delivery vehicles (novel AAV vectors) to deliver genes to any tissue or organ in the body. These customized products allow us to deliver normal genes to tissues with defective genes (as occurs in genetic diseases). This 4DMT discovery technology was originally developed...

Emerging Objects Corp.

BRIEF DESCRIPTION

Emerging Objects is an independent, creatively driven, 3D Printing MAKE-tank specializing in innovations in 3D printing architecture and building components. Emerging Objects' innovation lies in the unique approach to materials and sizes and the belief that 3D printing is the medium where good ideas become real.

UC Berkeley Professor of Architecture Ronald Rael co-founded Emerging Objects with San Jose State University Professor of Design Virginia San Fratello.

Timeline 2013. Company founded Inventors

Ronald Rael

Epigenetic Gene Editing

Brief Description

Epigenetic Gene Editing is a gene editing tools company dedicated to improvements in CRISPR-Cas9 editing by providing a fusion protein kit to gene editing companies.

Formerly known as EPI-CRISPRx.

Timeline 2021. Company founded Inventors

Enrique Lin Shiao, Jennifer Doudna

Demetrix, Inc.

Brief Description

Demetrix, Inc. works with nature to make rare ingredients readily accessible to promote healthier and happier lives. By using microorganisms such as baker's yeast and fermentation combined with the most advanced biotechnology, data science and automation, Demetrix can produce complex, sustainable ingredients at high purity and low cost. The company is initially focusing on producing cannabinoids to build its portfolio of ingredients. Exclusively licensed breakthrough technology from the University of California, Berkeley will soon enable Demetrix to commercially produce...

Rewrite Therapeutics

Brief Description

Rewrite Therapeutics accelerates drug development using a proprietary CRISPR-based evolution platform. For more information, contact Shakked Halperin.

Formerly known as Evolve Biotech, and Rewrite Biotech.

The company was acquired by Intellia Therapeutics in 2022.

Timeline 2018. Company founded 2022. Acquired by Intellia Therapeutics Inventor

Shakked Halperin

Genocea Biosciences, Inc.

Brief Description

Genocea finds targets of T cell responses to discover and develop life-changing medicines. The company created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases. Genocea designs its medicines using ATLASª, a proprietary technology platform. Genocea's platform has the potential to revolutionize vaccines and immunotherapies for a range of infectious diseases, cancers and autoimmune diseases. The...